Following approval by Emisphere shareholders, Novo Nordisk will acquire the company for a total of $1.8 billion.
List view / Grid view
Filter the results
Liraglutide (Saxenda) will be offered to adults with non-diabetic hyperglycaemia and a high risk of cardiovascular disease.
EPR’s Hannah Balfour explores pharma’s reputation prior to the pandemic and the impact of COVID-19, highlighting areas which pharma could focus on to improve consumer relations and drive public engagement and trust.
Mike Owen analyses how smart product information (PIM) management could be crucial in the future of pharma, given how large the industry continues to grow.
Novo Nordisk has set up a programme to allow patients in the US experiencing financial hardship because of COVID-19 to receive free insulin for 90 days.
The occurrence of non-fatal thrombotic events in Phase III study participants has called into question the safety of concizumab.
With the approval of the treatment, Rybelsus, there is a new option for treating type 2 diabetes without injections.
The two pharmaceutical companies are facing a legal battle after Mylan filed a new drug application for a generic of Novo Nordisk’s Victoza.
A report has suggested that the drug price reforms in the US will affect AstraZeneca and Novartis negatively, but Novo could benefit.
A new report predicts that the global diabetes drug market will rise to US$58.4 billion by 2025.
The FDA has approved an injection for use in patients aged 10-17 to treat type 2 diabetes.
It has been announced that a Marketing Authorisation Application (MAA) has been submitted to the European Medicines Agency (EMA) for oral semaglutide.
Letters have been sent to Eli Lilly, Novo Nordisk and Sanofi asking them to explain the rapidly increasing cost of insulin...
Circumventing evolution in cell factories can pave the way for commercialising new biobased chemicals to large-scale.